GRAFT-VERSUS-HOST DISEASE (GVHD)
Clinical trials for GRAFT-VERSUS-HOST DISEASE (GVHD) explained in plain language.
Never miss a new study
Get alerted when new GRAFT-VERSUS-HOST DISEASE (GVHD) trials appear
Sign up with your email to follow new studies for GRAFT-VERSUS-HOST DISEASE (GVHD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a lower dose of transplant drug boost quality of life for older cancer patients?
Disease control Recruiting nowThis study is for adults aged 60 and older with blood cancers who need a stem cell transplant. It compares a standard dose of a drug (cyclophosphamide) to a lower dose, both given after transplant to prevent graft-versus-host disease (GVHD), a common complication where donor cell…
Matched conditions: GRAFT-VERSUS-HOST DISEASE (GVHD)
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated May 17, 2026 03:01 UTC
-
New drug combo aims to reduce deadly transplant complication
Disease control Recruiting nowThis study tests whether a new combination of drugs (tacrolimus, methotrexate, and ruxolitinib) works better than the standard combination (cyclophosphamide, tacrolimus, and mycophenolate) at preventing graft-versus-host disease (GVHD) in people receiving stem cell transplants fo…
Matched conditions: GRAFT-VERSUS-HOST DISEASE (GVHD)
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug cocktail aims to tame deadly transplant complication
Disease control Recruiting nowThis study tests whether adding a new oral drug (ivarmacitinib) to standard medications can prevent acute graft-versus-host disease (GVHD) in 82 adults receiving a stem cell transplant from a female donor who has given birth. GVHD is a serious complication where donor cells attac…
Matched conditions: GRAFT-VERSUS-HOST DISEASE (GVHD)
Phase: PHASE2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Lower drug dose may ease stem cell transplant side effects
Disease control Recruiting nowThis study tests a lower dose of a drug called cyclophosphamide to prevent graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers like leukemia. GVHD occurs when donor cells attack the patient's body. The goal is to see if the lower dose wor…
Matched conditions: GRAFT-VERSUS-HOST DISEASE (GVHD)
Phase: PHASE2 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated May 11, 2026 20:50 UTC